Ematologia, Fondazione IRCCS Istituto Nazionale Dei Tumori
Welcome,         Profile    Billing    Logout  
 18 Trials 
46 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zinzani, Pier Luigi
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/25
08/26
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
05/25
04/27
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

Recruiting
3
120
Europe
Rituximab, Truxima, Zanubrutinib, Brukinsa
International Extranodal Lymphoma Study Group (IELSG)
Splenic Marginal Zone Lymphoma
05/29
05/29
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
TELLOMAK, NCT03902184 / 2018-003969-33: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Checkmark Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Dec 2022 - Dec 2022: Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Checkmark Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Sep 2022 - Sep 2022: Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Checkmark Preliminary efficacy data from stage 1 of TELLOMAK trial for mycosis fungoides at ICML 2021
More
Active, not recruiting
2
170
Europe, US
IPH4102, lacutamab
Innate Pharma
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
10/23
01/26
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen, a wholly owned subsidiary of Pfizer
Peripheral T-cell Lymphoma
05/24
12/25
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
01/25
07/29
FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting
2
56
Europe
Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
09/28
09/33
NCT06854653: A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Recruiting
2
115
Europe, US, RoW
PTX-100
Prescient Therapeutics, Ltd.
CTCL
01/28
06/28
MOLTO, NCT04082897 / 2018-005028-40: ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruiting
2
28
Europe
Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet
Niguarda Hospital
CLL Transformation
09/26
12/26
FIL_Tisle-HL, NCT05977673: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy

Recruiting
2
28
Europe
Tislelizumab
Fondazione Italiana Linfomi - ETS
Hodgkin Lymphoma
11/27
11/29
SIDNEY, NCT04669171 / 2020-003999-40: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Recruiting
1/2
60
Europe, US
EO2463, lenalidomide, Revlimid, rituximab, MabThera
Enterome
Follicular Lymphoma, Marginal Zone Lymphoma
05/26
05/32
ALPHA-2, NCT04416984: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Recruiting
1/2
160
Europe, Canada, US, RoW
ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Allogene Therapeutics
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
01/25
05/29
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26
NCT02576496: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Completed
1
106
Europe, US
Tinostamustine, EDO-S101
Mundipharma Research Limited
Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma
05/23
11/23
POSS, NCT06734078: An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated with Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme

Active, not recruiting
N/A
100
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
DLBCL - Diffuse Large B Cell Lymphoma
12/25
12/25
VAX4FRAIL, NCT04848493: National Project on Vaccines, COVID-19 and Frail Patients

Recruiting
N/A
1300
Europe
COVID-19 vaccines
Azienda Unità Sanitaria Locale Reggio Emilia, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Istituto Clinico Humanitas, IRCCS San Raffaele, Regina Elena Cancer Institute, Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS, University of Roma La Sapienza, Fondazione IRCCS Policlinico San Matteo di Pavia, Istituti Fisioterapici Ospitalieri, Istituto Tumori Giovanni Paolo II, BARI, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, IRCCS Azienda Ospedaliero-Universitaria di Bologna
COVID-19, Solid Tumor, Hematologic Diseases, Neurologic Disorder, Rheumatic Diseases
07/21
04/22
LYMPH-OS, NCT06814925: Italian Study of Patients with Lymphoma

Recruiting
N/A
1500
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lymphoma
08/26
08/26
RETRO-LYMPH, NCT06781437: Retrospective Observational Study of Italian Cohort of Lymphoma Patients

Recruiting
N/A
5500
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lymphoproliferative Syndrome, Autoimmune, Lymphoma
12/27
12/27
PRIMICI, NCT06781450: Study in Patients with Relapsed/refractory Primary Mediastinal Lymphoma Treated with Pembrolizumab or Nivolumab in Combination with Brentuximab Vedotin in a Real-life Context

Recruiting
N/A
50
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Primary Mediastinal B Cell Lymphoma
12/25
12/25
PIXBRIDGE, NCT06760936: Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients

Active, not recruiting
N/A
15
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Diffuse Large B Cell Lymphoma (DLBCL)
12/25
12/25
MEPI-AGE, NCT06761274: Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma

Recruiting
N/A
200
Europe
peripheral blood sampling
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hodgkin Lymphoma in Remission
09/25
09/25
SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context

Recruiting
N/A
65
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Castleman Disease
01/25
01/25
AMICO, NCT06814405: Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management with Early Discharge of Patients with Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital

Recruiting
N/A
100
Europe
Home patient management, Hospital patient management
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Haematological Malignancy
12/25
12/25
NCT03797170: Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma

Active, not recruiting
N/A
50
Europe
Gut microbiota samples
University of Bologna
Diffuse Large B Cell Lymphoma
07/23
12/23
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Recruiting
N/A
200
Europe
Incyte Biosciences Italy S.r.l, Advice Pharma Group srl
DLBCL - Diffuse Large B Cell Lymphoma
06/25
06/27
LNH012, NCT06026644: Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life

Active, not recruiting
N/A
170
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
DLBCL - Diffuse Large B Cell Lymphoma
02/24
04/26
NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Not yet recruiting
N/A
125
Europe
Zanubrutinib
Fondazione Italiana Linfomi - ETS
Waldenström's Macroglobulinemia (WM)
07/26
07/26
HL-SIP, NCT06733987: Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Recruiting
N/A
40
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hodgkin Lymphoma
02/27
02/27
CLIO, NCT06720701: Development of Prognostic Models for Response and Toxicity to CAR-T Cell Therapy in Patients with Relapsed/refractory Non Hodgkin's Lymphoma.

Not yet recruiting
N/A
125
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Non-Hodgkin Lymphoma
12/26
12/26
ZanOs, NCT06823960: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Recruiting
N/A
59
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Marginal Zone Lymphoma(MZL)
06/25
06/25
FIL_CTCL, NCT06588868: Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

Not yet recruiting
N/A
400
Europe
Fondazione Italiana Linfomi - ETS, Takeda
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
07/26
07/26
BRAF, NCT06781515: Assessment of Disease Burden in Hairy Cell Leukemia

Recruiting
N/A
45
Europe
Peripheral and BM blood sample
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hairy Cell Leukemia
11/25
11/25
FIL_MOGA, NCT06113081: Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

Recruiting
N/A
150
Europe
Fondazione Italiana Linfomi - ETS
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
05/25
07/25
MarZoLyOss, NCT06806488: Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas

Recruiting
N/A
160
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Marginal Zone B Cell Lymphoma
10/25
10/25
Endemato, NCT06851702: Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients with Hematological Malignancies and Subjected to Treatment with Immune-checkpoint Inhibitors

Recruiting
N/A
100
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hematological Malignancies
12/25
12/25
ACCELERATE, NCT02817997: International Registry for Patients With Castleman Disease

Recruiting
N/A
1000
US
University of Pennsylvania, EUSA Pharma, Inc., Castleman Disease Collaborative Network, Food and Drug Administration (FDA)
Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia, Angiofollicular Lymph Node Hyperplasia, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Giant Lymph Node, Lymph Node Hyperplasia, Giant
09/26
09/26
MicroCar, NCT05725720: Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy

Recruiting
N/A
90
Europe
Gut microbiome analysis
University of Bologna, Associazione Italiana per la Ricerca sul Cancro, IRCCS Azienda Ospedaliero-Universitaria di Bologna
Diffuse Large B Cell Lymphoma
07/27
12/27
NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Recruiting
N/A
300
Europe, US, RoW
International Extranodal Lymphoma Study Group (IELSG)
Nodal Marginal Zone Lymphoma
12/26
12/26
Rusconi, Chiara
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
NCT02371161 / 2013-003256-20: Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy

Recruiting
2
135
Europe
R-DHAP/R-ICE, R-DHAP or R-ICE and BEAM or FEAM
Fondazione Italiana Linfomi ONLUS
Non Hodgkin Lymphoma
12/18
02/23
FIL_Tisle-HL, NCT05977673: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy

Recruiting
2
28
Europe
Tislelizumab
Fondazione Italiana Linfomi - ETS
Hodgkin Lymphoma
11/27
11/29
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting
N/A
400
Europe
Treatment for clinical practise
Fondazione Italiana Linfomi ONLUS
Classical Hodgkin Lymphoma
01/26
01/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zinzani, Pier Luigi
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/25
08/26
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
05/25
04/27
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

Recruiting
3
120
Europe
Rituximab, Truxima, Zanubrutinib, Brukinsa
International Extranodal Lymphoma Study Group (IELSG)
Splenic Marginal Zone Lymphoma
05/29
05/29
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
TELLOMAK, NCT03902184 / 2018-003969-33: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Checkmark Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Dec 2022 - Dec 2022: Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Checkmark Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Sep 2022 - Sep 2022: Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Checkmark Preliminary efficacy data from stage 1 of TELLOMAK trial for mycosis fungoides at ICML 2021
More
Active, not recruiting
2
170
Europe, US
IPH4102, lacutamab
Innate Pharma
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
10/23
01/26
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen, a wholly owned subsidiary of Pfizer
Peripheral T-cell Lymphoma
05/24
12/25
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
01/25
07/29
FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting
2
56
Europe
Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
09/28
09/33
NCT06854653: A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Recruiting
2
115
Europe, US, RoW
PTX-100
Prescient Therapeutics, Ltd.
CTCL
01/28
06/28
MOLTO, NCT04082897 / 2018-005028-40: ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruiting
2
28
Europe
Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet
Niguarda Hospital
CLL Transformation
09/26
12/26
FIL_Tisle-HL, NCT05977673: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy

Recruiting
2
28
Europe
Tislelizumab
Fondazione Italiana Linfomi - ETS
Hodgkin Lymphoma
11/27
11/29
SIDNEY, NCT04669171 / 2020-003999-40: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Recruiting
1/2
60
Europe, US
EO2463, lenalidomide, Revlimid, rituximab, MabThera
Enterome
Follicular Lymphoma, Marginal Zone Lymphoma
05/26
05/32
ALPHA-2, NCT04416984: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Recruiting
1/2
160
Europe, Canada, US, RoW
ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Allogene Therapeutics
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
01/25
05/29
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26
NCT02576496: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Completed
1
106
Europe, US
Tinostamustine, EDO-S101
Mundipharma Research Limited
Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma
05/23
11/23
POSS, NCT06734078: An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated with Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme

Active, not recruiting
N/A
100
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
DLBCL - Diffuse Large B Cell Lymphoma
12/25
12/25
VAX4FRAIL, NCT04848493: National Project on Vaccines, COVID-19 and Frail Patients

Recruiting
N/A
1300
Europe
COVID-19 vaccines
Azienda Unità Sanitaria Locale Reggio Emilia, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Istituto Clinico Humanitas, IRCCS San Raffaele, Regina Elena Cancer Institute, Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS, University of Roma La Sapienza, Fondazione IRCCS Policlinico San Matteo di Pavia, Istituti Fisioterapici Ospitalieri, Istituto Tumori Giovanni Paolo II, BARI, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, IRCCS Azienda Ospedaliero-Universitaria di Bologna
COVID-19, Solid Tumor, Hematologic Diseases, Neurologic Disorder, Rheumatic Diseases
07/21
04/22
LYMPH-OS, NCT06814925: Italian Study of Patients with Lymphoma

Recruiting
N/A
1500
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lymphoma
08/26
08/26
RETRO-LYMPH, NCT06781437: Retrospective Observational Study of Italian Cohort of Lymphoma Patients

Recruiting
N/A
5500
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lymphoproliferative Syndrome, Autoimmune, Lymphoma
12/27
12/27
PRIMICI, NCT06781450: Study in Patients with Relapsed/refractory Primary Mediastinal Lymphoma Treated with Pembrolizumab or Nivolumab in Combination with Brentuximab Vedotin in a Real-life Context

Recruiting
N/A
50
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Primary Mediastinal B Cell Lymphoma
12/25
12/25
PIXBRIDGE, NCT06760936: Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients

Active, not recruiting
N/A
15
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Diffuse Large B Cell Lymphoma (DLBCL)
12/25
12/25
MEPI-AGE, NCT06761274: Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma

Recruiting
N/A
200
Europe
peripheral blood sampling
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hodgkin Lymphoma in Remission
09/25
09/25
SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context

Recruiting
N/A
65
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Castleman Disease
01/25
01/25
AMICO, NCT06814405: Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management with Early Discharge of Patients with Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital

Recruiting
N/A
100
Europe
Home patient management, Hospital patient management
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Haematological Malignancy
12/25
12/25
NCT03797170: Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma

Active, not recruiting
N/A
50
Europe
Gut microbiota samples
University of Bologna
Diffuse Large B Cell Lymphoma
07/23
12/23
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Recruiting
N/A
200
Europe
Incyte Biosciences Italy S.r.l, Advice Pharma Group srl
DLBCL - Diffuse Large B Cell Lymphoma
06/25
06/27
LNH012, NCT06026644: Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life

Active, not recruiting
N/A
170
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
DLBCL - Diffuse Large B Cell Lymphoma
02/24
04/26
NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Not yet recruiting
N/A
125
Europe
Zanubrutinib
Fondazione Italiana Linfomi - ETS
Waldenström's Macroglobulinemia (WM)
07/26
07/26
HL-SIP, NCT06733987: Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Recruiting
N/A
40
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hodgkin Lymphoma
02/27
02/27
CLIO, NCT06720701: Development of Prognostic Models for Response and Toxicity to CAR-T Cell Therapy in Patients with Relapsed/refractory Non Hodgkin's Lymphoma.

Not yet recruiting
N/A
125
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Non-Hodgkin Lymphoma
12/26
12/26
ZanOs, NCT06823960: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Recruiting
N/A
59
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Marginal Zone Lymphoma(MZL)
06/25
06/25
FIL_CTCL, NCT06588868: Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

Not yet recruiting
N/A
400
Europe
Fondazione Italiana Linfomi - ETS, Takeda
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
07/26
07/26
BRAF, NCT06781515: Assessment of Disease Burden in Hairy Cell Leukemia

Recruiting
N/A
45
Europe
Peripheral and BM blood sample
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hairy Cell Leukemia
11/25
11/25
FIL_MOGA, NCT06113081: Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

Recruiting
N/A
150
Europe
Fondazione Italiana Linfomi - ETS
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
05/25
07/25
MarZoLyOss, NCT06806488: Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas

Recruiting
N/A
160
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Marginal Zone B Cell Lymphoma
10/25
10/25
Endemato, NCT06851702: Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients with Hematological Malignancies and Subjected to Treatment with Immune-checkpoint Inhibitors

Recruiting
N/A
100
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hematological Malignancies
12/25
12/25
ACCELERATE, NCT02817997: International Registry for Patients With Castleman Disease

Recruiting
N/A
1000
US
University of Pennsylvania, EUSA Pharma, Inc., Castleman Disease Collaborative Network, Food and Drug Administration (FDA)
Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia, Angiofollicular Lymph Node Hyperplasia, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Giant Lymph Node, Lymph Node Hyperplasia, Giant
09/26
09/26
MicroCar, NCT05725720: Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy

Recruiting
N/A
90
Europe
Gut microbiome analysis
University of Bologna, Associazione Italiana per la Ricerca sul Cancro, IRCCS Azienda Ospedaliero-Universitaria di Bologna
Diffuse Large B Cell Lymphoma
07/27
12/27
NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Recruiting
N/A
300
Europe, US, RoW
International Extranodal Lymphoma Study Group (IELSG)
Nodal Marginal Zone Lymphoma
12/26
12/26
Rusconi, Chiara
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
NCT02371161 / 2013-003256-20: Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy

Recruiting
2
135
Europe
R-DHAP/R-ICE, R-DHAP or R-ICE and BEAM or FEAM
Fondazione Italiana Linfomi ONLUS
Non Hodgkin Lymphoma
12/18
02/23
FIL_Tisle-HL, NCT05977673: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy

Recruiting
2
28
Europe
Tislelizumab
Fondazione Italiana Linfomi - ETS
Hodgkin Lymphoma
11/27
11/29
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting
N/A
400
Europe
Treatment for clinical practise
Fondazione Italiana Linfomi ONLUS
Classical Hodgkin Lymphoma
01/26
01/26

Download Options